… disposition of orally administered drugs. This review also discusses BDDCS … transporters
and intestinal transporter-metabolizing enzyme interplay on oral drug pharmacokinetics. …

… hepatic transporters. Therefore, potential NASH-mediated changes in hepatic transporter
function could alter the pharmacokinetics and efficacy of these drugs in this patient population. …

… drug clearance in hepatically impaired patients using physiologically based pharmacokinetic
(… Correlation between the abundance of hepatic UGTs or transporters and log-transformed …

… transporter (OCT) family, and the pharmacokinetic or pharmacodynamic consequences for
organic cationic drugs. … for renal organic cation transporter OCT2 rather than hepatic OCT1. …

… Plasma exposure of a wide variety of drugs including OATP1B substrates is elevated in
hepatic impairment (HI). Disease-induced modulation in hepatic transporter expression was …

… of basolateral uptake transporters, an increase in efflux transporters, and modifications to …
increased drug exposure and adverse drug reactions (ADRs). Our goal was to predict drugs …

… Sometimes this may be a pharmacokinetic advantage for a drug, the target site of which is
the liver, but it may also be a pharmacokinetic disadvantage in terms of hepatic accumulation …

… that the sponsor should conduct hepatic transporter substrate assessment (eg OATP1B1 …
drugs hepatic uptake or elimination is significant (ie the drugs clearance via hepatic metabolism …

… of intestinal and hepatic P450s to drug metabolism and pharmacokinetics is also discussed.
… drug transporters and their involvement in clinically significant pharmacokinetic drug–drug …

… This article utilized the physiologically based pharmacokinetic (PBPK) liver model and its
extension that include heterogeneity in enzymes and transporters to illustrate how in vitro …